Functional brain imaging in the dementias: Role in early detection, differential diagnosis, and longitudinal studies

European Journal of Nuclear Medicine

Volumn 29, Issue 12, 2002, Pages 1685-1696

  Devous Sr , Michael D ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; Dementia; MRI; MRS; PET; SPET

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; CYSTEINE ETHYL ESTER TC 99M; FLUORODEOXYGLUCOSE F 18; GLUCOSE; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; N ACETYLASPARTIC ACID; TAU PROTEIN; XENON 133;

ALLELE; ALZHEIMER DISEASE; BRAIN BLOOD FLOW; BRAIN LEVEL; BRAIN METABOLISM; BRAIN PERFUSION; BRAIN REGION; BRAIN SIZE; CINGULATE GYRUS; CLINICAL TRIAL; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; DEMENTIA; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; EARLY DIAGNOSIS; GLUCOSE METABOLISM; HIPPOCAMPUS; HISTOPATHOLOGY; HUMAN; IMAGING SYSTEM; INTERMETHOD COMPARISON; LONGITUDINAL STUDY; MULTIINFARCT DEMENTIA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT PLANNING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE SEVERITY; FRONTOTEMPORAL DEMENTIA; LEWY BODY; MEDICAL ASSESSMENT; MINI MENTAL STATE EXAMINATION; PROGNOSIS; SCREENING TEST; SYMPTOM; TREATMENT OUTCOME; BRAIN; DIAGNOSTIC IMAGING; HISTOLOGY; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; REPRODUCIBILITY; SCINTISCANNING;

ALZHEIMER DISEASE; BRAIN; DEMENTIA; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC IMAGING; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0036454057     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-002-0967-2     Document Type: Review

References (73)

1. Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders: Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 1997; 278:1363-1371.
2. Bachman DL, Wolf PA, Linn RT, et al. Incidence of dementia and probable Alzheimer's disease in a general population: the Framingham study. Neurology 1993; 43:515-519.
3. Albert MS, Drachman DA. Alzheimer's disease: What is it, how many people have it, and why do we need to know? Neurology 2000; 56:166-168.
4. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA working group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 34:939-944.
5. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198.
6. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA 1994; 271:985-991.
7. Rogers SL, Friedhof LT. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 1996; 7:293-303.
8. Ryan DH. Misdiagnosis in dementia: Comparisons of diagnostic error rate and range of hospital investigation according to medical specialty. Int J Geriatr Psychiatry 1994; 9:141-147.
9. Chui H, Zang Q. Evaluation of dementia: a systematic study of the usefulness of the American Academy of Neurology's practice parameters. Neurology 1997; 49:925.
10. Van Heertum RL, Drocea C, Ichise M, Lobotesis K, Fawwaz RA. Single photon emission CT and positron emission tomography in the evaluation of neurologic disease. Radiol Clin North Am 2001; 39:1007-1033.
11. Devous MD Sr. SPECT functional brain imaging. Instrumentation, radiopharmaceuticals and technical factors. In: Van Heertum RL, Tikofsky RS, eds. Cerebral SPECT imaging, 3rd edn. Philadelphia: Lippincott, Williams and Wilkins; 2000:1-22.
12. Pucci E, Belardinelli N, Regnicolo L, et al. Hippocampus and parahippocampal gyrus linear measurements based on magnetic resonance in Alzheimer's disease. Eur Neurol 1998; 39:16-25.
13. Jack CR Jr, Petersen RC, Xu YC, et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology 1997; 49:786-794.
14. LeMay M, Stafford JL, Sandor T, et al. Statistical assessment of perceptual CT scan ratings in patients with Alzheimer's type dementia.J Comput Assist Tomogr 1986; 10:802.
15. George AE, de Leon MJ, Stylopoulos LA, et al. CT diagnostic features of Alzheimer's disease: Importance of the choroidal/hippocampal fissure complex. AJNR 1990; 11:101.
16. Silverman DHS, Small GW, Phelps ME. Clinical value of neu-roimaging in the diagnosis of dementia: Sensitivity and specificity of regional cerebral metabolic and other parameters for early identification of Alzheimer's disease. Clin Positron Imaging 1999; 2:119-130.
17. Mielke R, Heiss WD. Positron emission tomography for diagnosis of Alzheimer's disease and vascular dementia. J Neural Transm 1998; 53(Suppl):237-250.
18. Bonte FJ, Devous MD. Single-photon emission computed tomographic imaging of the brain. In: Sandler MP, Coleman RE, Wackers FJT, Patton JA, Gottschalk A, Hoffer PB, eds. Diagnostic nuclear medicine, 4th edn. Baltimore: Williams and Wilkins; 2002:in press.
19. Hoffman J M, Hanson MW, Welsh KA, et al. Interpretation variability of 18 FDG positron emission tomography studies in dementia. Invest Radiol 1996; 31:316-322.
20. Van Heertum RL, Tikofsky RS, Ruben AB. Dementia. In: Van Heertum RL, Tikofsky RS, eds. Functional cerebral SPECT and PET imaging, 3rd edn. New York: Lippincott Williams and Wilkins; 2000:127-188.
21. Masterman DL, Mendez MF, Fairbanks LA, et al. Sensitivity specificity and positive predictive value of technetium 99m-HMPAO SPECT in discriminating Alzheimer's disease from other dementias. J Geriatr Psychiatry Neurol 1997; 10:15.
22. Silverman DH, Small GW, Kung de Aburto MA, et al. Diagnostic accuracy of FDG-PET in evaluation of dementia: International multi-center pooled brain scan and autopsy data. J Nucl Med 2000; 41:63P.
23. Hoffman JM, Welsh-Bohmer KA, Hanson M, Crain B, Hulette C, Earl N, Coleman RE. FDG PET imaging in patients with pathologically verified dementia. J Nucl Med 2000; 41:1920-1928.
24. Jagust W, Thisted R, Devous MD Sr, Van Heertum R, Mayberg H, Jobst K, Smith AD, Borys N. SPECT perfusion imaging in the diagnosis of Alzheimer's disease: A clinical-pathologic study. Neurology 2001; 56:950-956.
25. Bonte FJ, Weiner MF, Bogio EH, White CL III. Brain blood flow in the dementias: SPECT with histopathologic correlation in 54 patients. Radiology 1997; 202:793-797.
26. Herholz K, Schopphoff H, Schmidt M, Mielke R, Eschner W, Scheidhauer K, Schicha H, Heiss WD, Ebmeier K. Direct comparison of spatially normalized PET and SPECT scans in Alzheimer's disease. J Nucl Med 2002; 43:21-26.
27. Clauss JJ, van Harskamp F, Breteler MB, et al. The diagnostic value of SPECT with Tc 99m HMPAO in Alzheimer's disease: A population based study. Neurology 1994; 44:454.
28. Johnson KA, Kijewski MF, Becker JA, Garada B, Satlin A, Holman BL. Quantitative brain SPECT in Alzheimer's disease and normal aging. J Nucl Med 1993; 34:2044-2048.
29. 99mTc-HMPAO SPECT data. J Neurol Neurosurg Psychiatry 2000; 69:661-663.
30. Imran MB, Kawashima R, Awata S, Sato K, Kinomura S, Ono S, Sato M, Fukata H. Tc 99m HMPAO SPECT in the evaluation of Alzheimer's disease: Correlation between neuropsychiatric evaluation and CBF images. J Neurol Neurosurg Psychiatry 1999; 66:228-232.
31. Molsa P, Parjavi L, Rinne J, Rinne U, Sako E. Validity of clinical diagnosis in dementia: A prospective clinicopathological study. J Neurol Neurosurg Psychiatry 1985; 48:1085-1090.
32. Morris JC, McKell DW, Storandt M, et al. Very mild Alzheimer's disease: Informant-based clinical, psychometric, and pathologic distinction from normal aging. Neurology 1991; 41:469-478.
33. Valenzuela MJ, Sachdev P. Magnetic resonance spectroscopy in AD. Neurology 2001; 56:592-598.
34. 1H MR spectroscopy study. Am J Psychiatry 1999; 156:1879.
35. Schuff N, Amend D, Ezekiel F, et al. Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease. Neurology 1997; 49:1513-1521.
36. Rose S, de Zubicaray G, Wang D, et al. A(1)H MRS study of probable Alzheimer's disease and normal aging: Implications for longitudinal monitoring of dementia progression. Magn Reson Imaging 1999; 17:291-299.
37. Parnetti L, Tarducci R, Presciutti O, et al. Proton magnetic resonance spectroscopy can differentiate Alzheimer's disease from normal aging. Mech Ageing Dev 1997; 97:9-14.
38. Doraiswamy M, Charles C, Krishnan R. Prediction of cognitive decline in early Alzheimer's disease. Lancet 1998; 352:1678.
39. Haxby JV, Grady CL, Koss E, et al. Longitudinal study of cerebral metabolic asymmetries and associated neuropsychological patterns in early dementia of the Alzheimer type. Arch Neurol 1990; 47:753.
40. Desgranges B, Baron JC, de la Sayette V, Petit-Taboue MC, Benali K, Landeau B, Lechevalier B, Eustache E. The neural substrates of memory systems impairment in Alzheimer's disease: A PET study of resting brain glucose utilization. Brain 1998; 121:611-631.
41. DeCarli CS, Atack JR, Ball MJ, Kaye JA, Grady CL, Fewster P, Pettigrew KD, Rapoport SI, Schapiro MB. Post-mortem regional neurofibrillary tangle densities but not senile plaque densities are related to regional cerebral metabolic rates for glucose during life in Alzheimer's disease patients. Neurodegeneration 1992; 1:113-121.
42. Rapoport SI. In vivo PET imaging and post-mortem studies suggest potentially reversible and irreversible stages of brain metabolic failure in Alzheimer's disease.Eur Arch Psychiatry Clin Neurosci 1999; 249 Suppl 3 III/46-III/55.
43. Rapoport SI, Grady CL. Parametric in vivo brain imaging during activation to examine pathological mechanisms of functional failure in Alzheimer's disease. Int J Neurosci 1993; 70:39-56.
44. Pietrini P, Furey ML, Alexander GE, Mentis MJ, Dani A, Guazzelli M, Rapoport SI, Schapiro MB. Association between brain functional failure and dementia severity in Alzheimer's disease: Resting versus stimulation PET study. Am J Psychiatry 1999; 156:470-473.
45. Mentis MJ, Alexander GE, Krasuski J, Pietrini P, Furey ML, Schapiro MB, Rapoport SI. Increasing required neural response to expose abnormal brain function in mild versus moderate or severe Alzheimer's disease: PET study using parametric visual stimulation. Am J Psychiatry 1998; 155:785-794.
46. Rogers SL, Friedhoff LT. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: An interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol 1998; 8:67-75.
47. Small GW, Mazziotta JC, Collins MT, et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 1995; 273:942-947.
48. Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S. Preclinical evidence of Alzheimer's disease in persons homozygous for the e4 allele for apolipoprotein E. N Engl J Med 1996; 334:752-758.
49. Morris JC, Storandt M, McKeel DW, et al. Cerebral amyloid deposition and diffuse plaques in "normal" aging: Evidence for presymptomatic and very mild Alzheimer's disease. Neurology 1996; 46:707-719.
50. Johnson KA, Jones K, Holman BL, et al. Preclinical prediction of Alzheimer's disease using SPECT. Neurology 1998; 50: 1563-1571.
51. Silverman DHS, Chang CY, Cummings JL, et al. Prognostic value of regional brain metabolism in evaluation of dementia: comparison with long-term clinical outcome [abstract].J Nucl Med 1999; 40:5(Suppl).
52. Salmon E, Sadzot B, Maquet P, et al. Differential diagnosis of Alzheimer's disease with PET. J Nucl Med 1994; 35:391-398.
53. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993; 43: 1467-1472.
54. Vickers JC, Dickson TC, Adlard PA, Saunders HL, King CE, McCormack G. The cause of neuronal degeneration in Alzheimer's disease. Prog Neurobiol 2000; 60:139-165.
55. Dickson TC, Saunders HL, Vickers JC. Relationship between apolipoprotein E and the amyloid deposits and dystrophic neurites of Alzheimer's disease. J Neuropathol Appl Neurobiol 1997; 23:483-494.
56. Okamura N, Arai H, Maruyama M, Higuchi M, Matsui T, Tanji H, Seki T, Hirai H, Chiba H, Itoh M, Sasaki H. Combined analysis of CSF tau levels and [(123)I]iodoamphetamine SPECT in mild cognitive impairment: implications for a novel predictor of Alzheimer's disease. Am J Psychiatry 2002; 159:474-476.
57. Ishii K, Sakmoto S, Sasaki M, et al. Cerebral glucose metabolism in patients with frontotemporal dementia. J Nucl Med 1998; 39:1875-1878.
58. Ishii K, Yamaji S, Kitgaki H, et al. Regional cerebral blood flow difference between dementia with Lewy bodies and AD. Neurology 1999; 53:413-416.
59. Albin RL, Minoshima S, D'Amato CJ, et al. Fluordeoxyglucose positron emission tomography and diffuse Lewy body disease. Neurology 1996; 47:462-466.
60. 99mTc-HMPAO single-photon emission computed tomography study of Lewy body disease. J Neurol 1997; 244:349-353.
61. Lobotesis K, Fenwick JD, Phipps A, Ryman A, Swann A, Ballard C, McKeith IG, O'Brien JT. Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology 2001; 56:643-649.
62. Bonte FJ, Devous MD Sr, Reisch JS, Ajmani AK, Weiner MF, Hom J, Tintner R. The effect of acetazolamide on regional cerebral blood flow in patients with Alzheimer's disease or stroke as measured by single-photon emission computed tomography. Invest Radiol 1989; 24:99-103.
63. Mielke R, Kessler J, Szelies B, et al. Vascular dementia: Perfusional and metabolic disturbances and effects of therapy. J Neurol Transm Suppl 1996; 47:183-191.
64. Kwan LT, Reed BR, Eberling JL, et al. Effects of subcortical cerebral infarction on cortical glucose metabolism and cognitive function. Arch Neurol 1999; 56:890-814.
65. 99mTc-HMPAO and the acetazolamide test and evaluation of vascular and Alzheimer's dementia. Eur J Nucl Med 1999; 26:239-245.
66. 99mTc-HMPAO SPECT in the investigation of dementia? J Neurol Neurosurg Psychiatry 1998; 64:306-313.
67. Small GW, Ercoli LM Silverman DHS, et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 2000; 97:6037-6042.
68. Jagust WJ, Haan MN, Reed BR, et al. Brain perfusion imaging predicts survival in Alzheimer's disease. Neurology 1998; 51:1009-1013.
69. Kogure D, Matsuda H, Ohnishi T, Asada T, Uno M, Kunihiro T, Nakano S, Takasaki M. Longitudinal evaluation of early Alzheimer's disease in brain perfusion SPECT. J Nucl Med 2000; 41:1155-1162.
70. Ashford J, Shih WJ, Coupal J, Shetty R, Schneider A, Cool C, Aleem A, Kiefer VH, Mendiondo MS, Schmitt FA. Single SPECT measures of cerebral cortical perfusion reflect time-index estimation of dementia severity and Alzheimer's disease. J Nucl Med 2000; 41:57-64.
71. Reiman EM, Uecker A, Caselli RJ, Bandy D, de Leon MJ, De Santi S, Convit A, Osborne D, Weaver A, Thibodeau SN. Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease. Ann Neurol 1998; 44:288-291.
72. Lehtovirta M, Kuikka J, Helisalmi S, Hartikainen P, Mannermas A, Ryynanen M, Riekkinen P Sr, Soininen H. Longitudinal SPECT study in Alzheimer's disease: Relation to apolipoprotein E polymorphism. J Neurol Neurosurg Psychiatry 1998; 64:742-746.
73. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997; 42:85-94.